**SYNTOMETRINE: LABOUR & BIRTH SUITE - QUICK REFERENCE GUIDE**

**Keywords:** syntometrine, oxytocic, ergometrine, third stage, postpartum haemorrhage prevention, active management of third stage, labour suite, LBS, QRG, uterotonic

**Note:** This Quick Reference Guide must be used in conjunction with its respective Clinical Guideline: Obstetrics & Midwifery, Intrapartum: Third Stage: Active Management

**KEY POINTS**

1. For active management of the third stage of labour, intramuscular oxytocin (not Syntometrine) should be the routine drug given.\(^2\)
2. Syntometrine\(^{\circledast}\) intramuscular injection is used for active management of the third stage of labour in women identified as high risk for postpartum haemorrhage (PPH) who do not have any contraindications to its use.
3. For postpartum haemorrhage management where oxytocin is not available or the bleeding does not respond to oxytocin, Syntometrine is recommended\(^4\) (if not already given for prophylaxis or contraindicated).
4. For PPH risks, prevention and management, see KEMH Clinical Guideline, Restricted Area Guidelines (Intranet only) Primary Postpartum Haemorrhage.
5. No more than 2 doses of ergometrine should be given due to the side-effects.\(^6\)

---

**SYNTOMETRINE - LABOUR & BIRTH SUITE**

**INDICATIONS:**
- Active management of the third stage of labour for women at high risk of PPH
- Prevention or treatment of PPH

**CONTRAINDICATIONS- DO NOT GIVE WHEN:**
- Hypertension / pre-eclampsia/ eclampsia
- Cardiac disease (moderate/severe) or severe peripheral vascular disease; severe hepatic or renal impairment; sepsis
- Unknown history (antenatal or medical) & imminent birth, including precipitous birth where blood pressure not checked
- Fibroids (severe); or allergy to oxytocin / ergometrine

**PRECAUTIONS- AVOID WITH:**
- Ischaemic heart disease; peripheral vascular disease; hypertension; migraine; Raynaud’s phenomenon; respiratory disease; chronic anaemia; or pregnancy
- Breech presentations- administer only after birth completed
- Multiple births (including possible undiagnosed multiple birth e.g. no pregnancy ultrasound)- give only after all fetuses have birthed

---

Note: This QRG represents minimum care & should be read in conjunction with the following information, Syntometrine, PPH & Third Stage: Active Management guidelines & relevant guidelines as required. Care should be individualised.
BACKGROUND
Syntometrine® contains oxytocin 5 units & ergometrine 0.5mg. 6, 8 The oxytocin within intramuscular Syntometrine acts rapidly (within 2 ½ minutes) and is short acting, whilst the ergometrine acts within 6-7 minutes and lasts 2-4 hours. 6 Associated side effects of ergometrine based medications include elevated blood pressure, nausea, vomiting, 6, 9, 10 vasoconstriction, dizziness, abdominal pain, headache and seizures. 11, 12 In hypertensive women, syntometrine can worsen hypertension and is contraindicated. 2 A UK report 2 on maternal mortality recommends that the routine use of syntometrine be avoided completely (p.69), with preference given to using intramuscular oxytocin (without ergometrine).

INDICATIONS FOR USE 8, 15
1. Active management of the third stage of labour
2. Prevention or treatment of PPH. See Risk Factors for PPH section on next page.

CONTRAINDICATIONS TO THE USE OF SYNTOMETRINE®
- Pre-eclampsia 15 or eclampsia, 12 hypertensive disorders 12
- Moderate-to-severe cardiac disease or severe peripheral vascular disease 15
- No knowledge of the woman’s antenatal and medical history and the birth is imminent, including women with precipitous labours in whom blood pressure has not been checked. 2
- Severe hepatic impairment 15, renal failure or sepsis 8 - avoid use as sensitivity to ergometrine is increased 12
- Severe fibroids 15; allergy to oxytocin 18 or ergometrine 8

NB: Although pre-eclampsia 5, 14 hypertensive disease in pregnancy 1, 3, 7, severe fibroids 15 and sepsis are identified risk factors for postpartum haemorrhage, women with these conditions must not be given Syntometrine.

PRECAUTIONS
- Pre-existing pulmonary, cardiac or vascular disorders: Ischaemic heart disease, peripheral vascular disease or hypertension may be exacerbated 15; migraine; Raynaud’s phenomenon (extreme vasoconstriction of peripheral blood vessels) 12; respiratory disease or chronic anaemia
- Pregnancy 8 - Category C; Not indicated 15
- Breech presentations – ensure administration occurs after the birth is completed 8
- Multiple births - ensure that administration only occurs after the birth of the last fetus 8 (e.g. second twin) otherwise excessive uterine contraction can result in death of the subsequent fetus(es). 15 If possibility of an undiagnosed second twin (e.g. no ultrasound in pregnancy), exercise caution before administering oxytocic. 10
RISK FACTORS FOR PPH

An increased risk of PPH is associated with:

- **Demographics**: Age (>35); Ethnicity (Asian, or Hispanic); Obesity (BMI > 35)
- **Medical history**: Anaemia (< 9g/dL); Medical disorders (e.g. Von Willebrand’s/ coagulopathies, or diabetes); Anticoagulant therapy
- **Previous obstetric history**: Past history of PPH, retained placenta or MROP; previous caesarean birth
- **Antenatal history**: Antepartum haemorrhage; Chorioamnionitis; Over-distended uterus (polyhydramnios, multiple gestation, macrosomia); Grand multiparity; parity 5 or more; Primigravidity; Placental abnormalities e.g. Placenta praevia, or suspected / proven abruptio placenta; Tocolytic drugs (e.g. Antepartum use of magnesium sulphate, nifedipine, salbutamol); Fetal demise
- **Labour**: Induction of labour or augmentation; Oxytocin exposure in labour (prolonged use or higher maximal dose); Malpresentation (other than cephalic); Prolonged labour (e.g. First stage ≥ 12hrs, Second stage ≥ 3hrs) or third stage; Pyrexia in labour; Rapid or in-coordinate labour
- **Birth**: Caesarean section or operative /instrumental vaginal birth; Episiotomy - mediolateral; General anaesthetic; Retained placenta or products; Uterine inversion; uterine rupture or cervical laceration; Mismanaged third stage (massaging uterus causing partial separation of placenta)

**Note**: PPH may occur when there are no risk factors identified.

* See Precautions on previous page.

See also Restricted Area Guidelines (Intranet only): Postpartum Haemorrhage
REFERENCES / STANDARDS


National Standards – 1- Care Provided by the Clinical Workforce is Guided by Current Best Practice; 4- Medication Safety

Legislation – Poisons Act 1964

Related Policies – OD 0324/11 Consent to Treatment for the Western Australian Health System 2011

Other related documents –

KEMH Clinical Guidelines:
- Obstetrics & Midwifery, Intrapartum: Birth Management; Labour (Third Stage) Active Management; Expectant (Physiological) Management; Retained Placenta; Medications During Labour & Birth: Guidelines for Prescribing;
- Obstetrics & Midwifery, Intrapartum: Guidelines for Prescribing in the Family Birth Centre: Oxytocic for Third Stage in FBC; Ergometrine for PPH in FBC; Syntometrine for Third Stage in FBC
- Pharmacy: Syntometrine; Administration of Medications
- Restricted Area Guidelines (Intranet only): Primary Postpartum Haemorrhage (PPH)

MR810.04 Medication Administered for Labour & Birth

<table>
<thead>
<tr>
<th>RESPONSIBILITY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Policy Sponsor</td>
</tr>
<tr>
<td>Initial Endorsement</td>
</tr>
<tr>
<td>Last Reviewed</td>
</tr>
<tr>
<td>Last Amended</td>
</tr>
<tr>
<td>Review date</td>
</tr>
</tbody>
</table>

Do not keep printed versions of guidelines as currency of information cannot be guaranteed.
Access the current version from the WNHS website.

© Department of Health Western Australia 2015